

Accelerate Your IND timeline by 2-3 months with Integrated DS+DP Solutions
Fragmented DS and DP development is one of the most common reasons
IND timelines slip—often by months.
Traditional sequential development often locks in Drug Substance (DS) decisions before Drug Product (DP) risks are even understood, triggering late-stage formulation failures and costly rework.
At Aragen Life Sciences, we’ve pioneered the “Follow the Molecule” approach—a synchronized, parallel workflow that eliminates silos and puts your molecule on the fast track.
What you gain with Aragen Integrated approach?
The Power of Parallel Execution
| Traditional (Sequential) | Aragen Integrated (Parallel) |
| Longer, fragmented timelines | Shorter, DS+DP workflows |
| High risk of late-stage surprises | Early risk identification and mitigation |
| Siloed decision-making | Strong cross-functional integration |
| Delayed patient access | Accelerated delivery of life-changing medicines |
Don’t leave your IND to chance.
Transform your CMC liabilities into strategic competitive advantages. Our experts use Quality by Design (QbD) principles and advanced particle engineering to ensure your molecule is not just fast, but robust and regulatory-ready.
Ready to accelerate your timeline? Fill out the form to consult with our integrated solutions team and learn how we can recover months on your next program.